IIS are independent clinical research projects that are conceived, initiated, conducted, and sponsored by a qualified third-party investigator (Sponsor Investigator). The Sponsor Investigator can be an individual investigator or an Institution and is responsible for fulfilling the applicable legal and regulatory requirements and any obligations as study sponsor.
IIS contribute to answer important medical and scientific questions and to advance knowledge about Stryker products or general disease states of interest to the medical community.
In line with Stryker’s mission “Together with our customers, we are driven to make healthcare better”, Stryker IVS is committed to advancing healthcare and improving patients’ lives. As part of this commitment, Stryker IVS believes in the value of supporting the independent research projects that are in line with the company clinical strategy and that are based on Stryker’s IVS portfolio, which includes:
How does Stryker IVS IIS program work?
Stryker IVS may support those IIS that are in line with the company clinical strategy, the defined areas of interest, and the identified divisional clinical data needs in the form of funding or by providing Stryker IVS devices.To be considered for Stryker’s support, the proposed IIS must be designed to produce data, results and conclusions that have scientific value to the medical or patient community and must offer robustness in terms of ethical and scientific design.
Note: Stryker support is limited to coverage of financial expenses (whether via funds or in-kind) and/or supply of Stryker products, without exceeding fair market value. Funding requests for expenses not associated with the conduct of the study are prohibited.
Qualifications of the Sponsor Investigator
The Sponsor Investigator must be able to demonstrate evidence of high ethical and scientific standards as it relates to clinical research in human subjects and must be experienced in undertaking clinical research either as a sponsor or by participating to research sponsored by credible organizations.
The IIS is submitted to Stryker by the Sponsor Investigator.
The proposal is evaluated by the Stryker IVS multidisciplinary review Committee within 30 days following the submission.
The submitting investigator is informed about the review outcome. If the review results in an approval to move forward with supporting the study, an agreement will be executed with the research partner.
Note: The outcome of a proposal's review is not contingent on past, current or future business relationship between Stryker and the research partner.
Request additional information
Complete the form below to ask questions or to let us know that you are interested.
The SpineJack® system is indicated for use in the reduction of mobile spinal fractures that may result from osteoporosis, trauma (fracture type A according to the Magerl classification), and malignant lesions (myeloma or osteolytic metastasis). The SpineJack® system is intended to be used in combination with validated bone cement, and to be placed, using a transpedicular approach, through a vertebra pedicle with a minimum internal diameter (see the Specifications section), as verified with a preoperative CT scan.
Bone cement: serious adverse events, some with fatal outcome, associated with the use of bone cements for vertebroplasty, kyphoplasty and sacroplasty include myocardial infarction, cardiac arrest, cerebrovascular accident, pulmonary embolism and cardiac embolism. Although it is rare, some adverse events have been known to occur beyond a year or more postoperatively. Additional risks exist with the use of bone cement. Please see the IFU for a complete list of potential risks.
This website is intended solely for the use of healthcare professionals. A surgeon must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that surgeons be trained in the use of any particular product before using it in surgery.
The information presented is intended to demonstrate a Stryker product. A surgeon must always refer to the package insert, product label and/or instructions for use, including the instructions for cleaning and sterilization (if applicable), before using any Stryker product. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Stryker representative if you have questions about the availability of Stryker products in your area.
Stryker Corporation or its affiliates own, use, or have applied for the following trademarks or service marks: Stryker Corporation or its divisions or other corporate affiliated entities own, use or have applied for the following trademarks or service marks: AVAflex, AutoPlex, iVAS, MultiGen, PCD, SpineJack, SpinePlex, Stryker, Venom, VertaPlex and VertePort. All other trademarks are trademarks of their respective owners or holders. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Sales Representative if you have questions about the availability of our products in your area. All other trademarks are trademarks of their respective owners or holders.